É. Toulza

[Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study].

V. Lieutenant, É. Toulza, M. Pommier, 2015, Bulletin du cancer.

Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.

J. Blay, S. Mathoulin-Pélissier, M. Toulmonde, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

LBA67 TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas

J. Blay, S. Mathoulin-Pélissier, M. Toulmonde, 2020 .

Detection of drug safety signals from clinical trials data: Role of SUSARs

J. Montastruc, F. Salvo, B. Lortal, 2018, Pharmacological research.

Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study.

A. Italiano, C. Bellera, E. Paillaud, 2020, Journal of geriatric oncology.

A single center evaluation of cost savings related to treatment‐free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco‐economy larger study

F. Durrieu, F. Mahon, A. Schmitt, 2020, British journal of haematology.